Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy

por Clausse, V, Goloudina, A R, Uyanik, B, Kochetkova, E Y, Richaud, S, Fedorova, O A, Hammann, A, Bardou, M, Barlev, N A, Garrido, C, Demidov, O N
Publicado 2016

Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel–Trenaunay syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, s...

por Luu, M., Vabres, P., Devilliers, H., Loffroy, R., Phan, A., Martin, L., Morice-Picard, F., Petit, F., Willems, M., Bessis, D., Jacquemont, M. L., Maruani, A., Chiaverini, C., Mirault, T., Clayton-Smith, J., Carpentier, M., Fleck, C., Maurer, A., Yousfi, M., Parker, V. E. R., Semple, R. K., Bardou, M., Faivre, L.
Publicado 2021